ATE414711T1 - Polymerstabilisierte proteinasen - Google Patents

Polymerstabilisierte proteinasen

Info

Publication number
ATE414711T1
ATE414711T1 AT02744682T AT02744682T ATE414711T1 AT E414711 T1 ATE414711 T1 AT E414711T1 AT 02744682 T AT02744682 T AT 02744682T AT 02744682 T AT02744682 T AT 02744682T AT E414711 T1 ATE414711 T1 AT E414711T1
Authority
AT
Austria
Prior art keywords
proteinases
polymer
stabilized
admixture
stabilization
Prior art date
Application number
AT02744682T
Other languages
English (en)
Inventor
Merry Sherman
Alexa Martinez
Shyam Bhaskaran
L Williams
Mark Saifer
John A French
Original Assignee
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals
Application granted granted Critical
Publication of ATE414711T1 publication Critical patent/ATE414711T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02744682T 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen ATE414711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89407101A 2001-06-28 2001-06-28
US10312802A 2002-03-22 2002-03-22

Publications (1)

Publication Number Publication Date
ATE414711T1 true ATE414711T1 (de) 2008-12-15

Family

ID=26800115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02744682T ATE414711T1 (de) 2001-06-28 2002-06-28 Polymerstabilisierte proteinasen

Country Status (8)

Country Link
US (1) US7229810B2 (de)
EP (1) EP1421175B1 (de)
AT (1) ATE414711T1 (de)
AU (1) AU2002345938A1 (de)
CA (1) CA2450985A1 (de)
DE (1) DE60229958D1 (de)
DK (1) DK1421175T3 (de)
WO (1) WO2003002716A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US20030170617A1 (en) 2002-01-28 2003-09-11 Pasloske Brittan L. Crude biological derivatives competent for nucleic acid detection
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
PT1625156E (pt) * 2003-05-12 2013-01-09 Affymax Inc Novos péptidos que se fixam ao receptor da eritropoietina
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
CA2597482A1 (en) * 2005-02-11 2006-08-17 Invitrogen Dynal As Method for isolating nucleic acids comprising the use of ethylene glycol multimers
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070212865A1 (en) * 2006-03-08 2007-09-13 Craig Amrine Method for planarizing vias formed in a substrate
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2367954B1 (de) * 2008-12-19 2015-02-18 Life Technologies Corporation Proteinase k inhibitore, verfahren und zusammensetzungen davon
CN112135837A (zh) * 2018-03-14 2020-12-25 勇·巴 聚乙二醇化抗冻蛋白及其制备和使用方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS5816685A (ja) 1981-07-22 1983-01-31 Takeda Chem Ind Ltd 固定化酵素，その製造法および製剤
JPS57118789A (en) 1981-01-13 1982-07-23 Eisai Co Ltd Modified streptokinase and its preparation
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4844897A (en) 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US5278062A (en) 1987-04-03 1994-01-11 Amgen Proteolytic enzymes
US5006333A (en) 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5246849A (en) 1988-04-12 1993-09-21 Enzon, Inc. Thermally stable serine proteases
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US4962020A (en) 1988-07-12 1990-10-09 President And Fellows Of Harvard College DNA sequencing
US5498523A (en) 1988-07-12 1996-03-12 President And Fellows Of Harvard College DNA sequencing with pyrophosphatase
JPH02219571A (ja) * 1989-02-20 1990-09-03 Kanebo Ltd 修飾プロテアーゼ及びその製造法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
ATE191510T1 (de) 1991-09-24 2000-04-15 Keygene Nv Selektive restriktionsfragmentenamplifikation: generelles verfahren für dns-fingerprinting
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5482996A (en) * 1993-12-08 1996-01-09 University Of Pittsburgh Protein-containing polymers and a method of synthesis of protein-containing polymers in organic solvents
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU697440B2 (en) * 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
US5837517A (en) 1995-05-05 1998-11-17 Novo Nordisk A/S Protease variants and compositions
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
KR100591553B1 (ko) 1996-11-04 2006-06-19 노보자임스 에이/에스 섭틸라제 변종과 조성물
US6416756B1 (en) * 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
EP1017794A1 (de) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptid-polymer-konjugate mit hinzugefügten oder entfernten bindungsgruppen
ES2296336T3 (es) 1997-06-25 2008-04-16 Novozymes A/S Polipeptido modificado.
US5847110A (en) * 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
US6495136B1 (en) * 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
BR9912158A (pt) * 1998-07-17 2001-04-10 Novozymes As Conjugado de polipeptìdeo-polìmero, composição industrial, uso de um conjugado, e, método para melhorar o desempenho de lavagem de um polipeptìdeo.
IL141220A0 (en) 1998-08-06 2002-03-10 Mountain View Pharmaceuticals Conjugates of peg-urate oxidase and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin

Also Published As

Publication number Publication date
CA2450985A1 (en) 2003-01-09
US7229810B2 (en) 2007-06-12
EP1421175B1 (de) 2008-11-19
AU2002345938A1 (en) 2003-03-03
DK1421175T3 (da) 2009-03-23
WO2003002716A2 (en) 2003-01-09
WO2003002716A3 (en) 2003-10-16
EP1421175A2 (de) 2004-05-26
US20030012777A1 (en) 2003-01-16
DE60229958D1 (de) 2009-01-02
EP1421175A4 (de) 2004-12-08

Similar Documents

Publication Publication Date Title
DE60229958D1 (de) Polymerstabilisierte proteinasen
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
ATE542922T1 (de) 2'-terminator-assoziierte pyrophosphorolyse- aktivierte polymerisierung
HRP20070012A2 (en) Immunostimulatory oligonucleotide multimers
NO20034751D0 (no) Antranilsyreamider, deres fremstilling og anvendelse samt preparater
WO2004022701A3 (en) Exponential amplification of nucleic acids using nicking agents
DE60329220D1 (de) Antisense-entwurf
DK1232502T3 (da) Magnetiske glaspartikler, fremgangsmåde til deres fremstilling samt anvendelser deraf
WO2007040592A8 (en) Making nucleic acid sequences in parallel and use
DK1899462T3 (da) Stabile vandige systemer omfattende proteiner
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2005003296A3 (en) Albumin fusion proteins
EP1608732A4 (de) Zusammensetzungen und verfahren zur verwendung einer synthetischen dnase i
BRPI0413967A (pt) polìmero solúvel em água, processo para preparar um polìmero solúvel em água, composição e solução aquosa
WO2002014485A3 (en) Kallikrein gene
WO2004096842A3 (en) Sars virus nucleotide and amino acid sequences and uses thereof
WO2003030821A3 (en) Albumin fusion proteins
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
BR9904054A (pt) Proteìnas que se ligam a diarilsulfoniluréia
BRPI0513267A (pt) variantes melhoradas de aprotinina
NO20024959D0 (no) Polyamidnukleinsyrederivater, midler og fremgangsmåter for deres fremstilling
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
WO2005047462A3 (en) Universal control for nucleic acid amplification
ATE369429T1 (de) Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1421175

Country of ref document: EP